Contact Information

Carol Stewart, CMP, CHSE Lead Coordinator

McMaster University, Continuing Health Sciences Education

 905-525-9140 ext. 20052

castewa@mcmaster.ca

McMaster University, Continuing Health Sciences Education (CHSE)

 

MAILING ADDRESS
McMaster University, Continuing Health Sciences Education
1280 Main St. W., DBHSC, Room 5004, Hamilton, ON L8S 4K1 

 

DELIVERY ADDRESS 
McMaster University, Continuing Health Sciences Education
100 Main Street West, 5th Floor, Room 5004, Hamilton, ON L8P 1H6

 

P: 905-525-9140 ext. 22671
F: 905-572-7099


cme@mcmaster.ca

Day 1: Sunday September 30, 2018

1700-1900     Registration and Dinner

1900-1910     Welcome and introductory Remarks (Steinberg, Jones, Shaw)

 

Session 1:  Energy sensing and AMPK

 

1910-1940     Steven Britton (University of Michigan, USA): A non-equilibrium thermodynamic approach to energy metabolism and disease

1940-2000     Graham Hardie (University of Dundee): AMPK: A historical perspective

2000-2100     Arrival Reception (Sponsored by the Biochemical Journal)

 

Day 2: Monday October 1, 2018

 

0730-0830     Breakfast

 

Session 2:  AMPK Structure-function relationships 

 

0830-0900     Bruce Kemp (St. Vincent’s Institute, Australia): Structure function insights into the CaMKK2-AMPK signalling pathway

0900-0930     Karsten Melcher  (Van Andel Research Institute, US): Structural insight into AMPK in different activity states   

  

0930-1000     Sheng-Cai Lin (Xiamen University, China): Mechanism for aldolase to transmit FBP/glucose starvation to AMPK activation

1000-1015     Kevin Ngoei (St. Vincent’s Institute, Australia): Structural determinants for small-molecule activation of skeletal muscle AMPKa2b2g1 by SC4

 

1015-1045     Coffee Break

Session 3:  Obesity and Metabolism

1045-1115     Steve Shoelson (Harvard University, US): How obesity desensitizes AMPK: In vivo multi-omics, mechanism studies, and results for safely restoring AMPK sensitivity

 

1115-1145     Erik Richter (University of Copenhagen, Denmark): AMPK in metabolic regulation and exercise

 

1145-1215     Dave Carling (Imperial College, UK): Investigating the effect of AMPK activation in vivo

 

1215-1230     Ian Salt (University of Glasgow, UK): AMP-activated protein kinase complexes containing the beta2 regulatory subunit are upregulated during and contribute to adipogenesis

 

1230-1330     Lunch 

Session 4:  Diabetes and Metabolism

1330-1400     Rasmus Kjøbsted (University of Copenhagen, Denmark): Role of AMPK in regulating skeletal muscle metabolism

1400-1430     Laurie Goodyear (Harvard University, US): Mechanism for the Beneficial Effects of Maternal Exercise On Offspring Liver Metabolism

1430-1445     Yasuhiko Minokoshi (National Institutes of Natural Sciences, Japan): Activation of AMPK-regulated CRH neurons in the PVH induces dietary selection for carbohydrate over fat

 

1445-1515     Coffee Break

 

Session 5:  Diabetes and Metabolism (Continued) 

1515-1545     Kei Sakamoto (Nestle, Switzerland): Regulation and role of AMPK in liver

1545-1615     Greg Steinberg (McMaster, Canada): AMPK regulation of lipid metabolism

1615-1630     Franziska Kopietz (Lund University, Sweden): Evaluation of the effect of different AMPK activators on glucose uptake in rat and human adipocytes 

 

1630-1645     Manuel Johanns (Université catholique de Louvain, Belgium): Inhibition of hepatic gluconeogenesis by pharmacological AMPK activation

1645-1700     Bruno Guigas (Leiden University, Netherlands), Dendritic cell-specific deletion of LKB1 aggravates high-fat diet-induced insulin Resistance  

1700-1800     Free Time

1800-1900     Dinner

Session 6:  Poster Presentations 

(Sponsored by the Biochemical Journal and the International Journal of Molecular Sciences)

1900-2100       Abstracts 1-30

 

                                    

 

Day 3: Tuesday October 2, 2018

 

0730-0830     Breakfast

 

Session 7:  Cardiovascular Disease 

 

0830-0900     Sandrine Horman (Université catholique de Louvain, Belgium): New insights into the role of AMPK-ACC signaling in platelet biology 

 

0900-0930     Ming-Hui Zou (University of Georgia, US): AMPK in atherosclerosis

 

0930-0945     Morgan Fullerton (University of Ottawa, Canada) Therapeutic targeting of macrophage AMPK in atherosclerosis

 

0945-1000     Uwe Schlattner (Universite de Grenoble, France) Cardiac AMPK and its potential role in doxorubicin cardiotoxicity

 

1000-1030     Coffee Break

Session 8:  Cardiovascular Disease (continued)

1030-1100     Regine Heller (Jena University ,Germany): AMPK in endothelial cells: regulation and multiple functions

 

1100-1130     Luc Bertrand (Université catholique de Louvain, Belgium): Reduction of O-GlcNAcylation by AMPK, a master event in cardiac hypertrophy inhibition 

 

1130-1145     Brendan Gongol (Loma Linda University, US): AMPK regulates endothelial miRNA biogenesis through nucleolin  

 

1145-1200     Vladimir Ljubicic (McMaster University, Canada): The effect of AMPK on the neuromuscular junction  

 

1200-1300     Lunch 

Session 9:  Aging 

1300-1330     Will Mair (Harvard University, US): AMPK and mTORC1: Shared or Separable Longevity Modifiers

 

1330-1400     Jay Chung (NIH, US): DNA-PK and AMPK in aging-related decline in mitochondrial function

 

1400-1415     Justin Crane (Northeastern University, US) AMPK deletion in the epidermis of adult skin leads to stress-induced hyperproliferation  

 

1415-1430     Manuel Matzinger (University of Vienna, Austria). Identification of AMPK-dependent phosphorylation sites in the transcription factor Nrf2 and their functional relevance in cells 

 

1430-1500     Coffee Break

Session 10:  Emerging Roles for AMPK

 

1500-1530     Benoit Viollet (Institut Cochin, France): Contribution of AMPK in the maintenance of intestinal epithelial barrier function

 

1530-1600     Arnim Pause (McGill University, Canada): The transcription factors TFEB and TFE3 link the FLCN-AMPK signaling axis to innate immune response and pathogen resistance

 

1600-1615     Xuewen Song (University of Toronto, Canada) AMPK drug re-purposing for experimental treatment of autosomal dominant polycystic kidney disease (ADPKD)

 

1615-1630     Liting Hang (National University of Singapore): AMPK-PGC-1a axis in neuroprotection – implications for energy deficits in Parkinson’s disease

 

1630-1645     Pallavi Gurung (Republic of Korea): 5-Hydroxytrptamine induces inflammasome formation and pyroptosis via suppression of AMPK activity  

 

1645-1700     Shailendra Giri (Henry Ford Hospital, US): AMP-activated protein kinase-mediated regulation of the NLRP3 inflammasome under neuro-inflammation 

 

1700-1800     Free Time

1800-1900     Dinner

Session 11:  Poster Presentations

1900-2100     Abstracts 31-60

 

 

 

Day 4: Wednesday October 3, 2018

 

0730-0830     Breakfast

Session 12:  Cancer Metabolism 

0830-0900     Grahame Hardie (University of Dundee, UK): AMPK - tumor suppressor or tumor promoter?

 

0900-0930     Reuben Shaw (Salk Institute, US): Taking apart the fuel gauge: parsing AMPK effectors from cancer to metformin

 

0930-0945     Adrien Grenier (Institut Cochin, France): PERK is a novel AMPK target involved in apoptotic response to chemical AMPK activation in acute myeloid leukemia

 

1000-1030     Coffee Break

 

Session 13:  Cancer Metabolism and AMPK Related Kinases

1030-1100     Rusty Jones (Van Andel Research Institute, US): Connecting inflammation and tumour progression through LKB1

 

1100-1130     Daniel Murphy (University of Glasgow, UK): Tumor-protective roles of NUAK1 in MYC-driven cancers

 

1130-1145     Biplab Dasgupta (University of Cincinnati, US): The dichotomy of AMPK – mTOR signaling in mammalian tissues

 

1145-1200     Sang-Min Jeon (Republic of Korea): AMPK regulates KEAP1-NRF2 pathway during metabolic stress to promote antioxidant defense in cancer

 

1200-1300     Lunch 

 

Session 14:  AMPK activating therapeutics

 

1300-1330     Robert Myers (Merck, US): The Development and Pharmacology of MK-8722, a Potent, Systemic Pan-AMPK Activator

 

1330-1400     Russell Miller (Pfizer, US): Skeletal muscle AMPK activation as a therapeutic treatment for diabetes and the cardiometabolic syndrome

 

1400-1430     Sophie Hallakou-Bozec(Poxel, France):  PXL770, a direct AMPK activator for the treatment of NASH 

 

1430-1500     Thomas Edlund (Betagenon, Sweden): AMPK activator O304 exhibits beneficial metabolic, microvascular and hemodynamic effects in patients with type 2 diabetes

 

1530-2100     Bus tour and boat ride to see Niagara Falls followed by dinner at winery with presentation and poster awards and closing remarks            

 

Day 5: Thursday October 4, 2018

0730-0900     Breakfast

 

0900-1130     Informal Collaborative Discussions, Touring of Local Attractions

 

1130              Departure